MET in NSCLC is suppressed via EGFR, JUN, F2 downregulation, stimulatory effects of P38MAPK upregulation does not affect resulting trend towards the MET suppression; in SCLC, suppression is achieved via combined downregulation of F2, EGFR, ITGB4, NRP1, P38MAPK; therefore, we should expect a higher level of MET in NSCLC than in SCLC specimens. The gene discussed is EGFR; the disease is small cell lung carcinoma.